Neoadjuvant and Adjuvant Therapy for Non-Small Cell Lung Cancer.
Hematol Oncol Clin North Am
; 31(1): 31-44, 2017 02.
Article
em En
| MEDLINE
| ID: mdl-27912832
ABSTRACT
The use of 4 cycles of cisplatin-based adjuvant chemotherapy is now the standard of care for patients with resected stage II and IIIA non-small cell lung cancer. Neoadjuvant chemotherapy lacks the same level of data as adjuvant treatment, but meta-analyses of this approach support its use. Selection of patients who are most likely to benefit from chemotherapy remain elusive. Ongoing adjuvant trials are exploring biomarkers, molecularly targeted agents, postoperative radiation therapy, and immunotherapy.
Palavras-chave
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Biomarcadores Tumorais
/
Carcinoma Pulmonar de Células não Pequenas
/
Terapia Neoadjuvante
/
Neoplasias Pulmonares
Limite:
Humans
Idioma:
En
Ano de publicação:
2017
Tipo de documento:
Article